Fluor's $27 Billion "Cheap" Is the Metric the 249% Run Depends On

The consensus on Fluor is generous, and in one narrow respect it is exactly right. The engineer has been renamed a growth story: shares near $54 after more than tripling from their low, and up more than 30% this year. The bull case rests on a single magnificent digit — a $26.9 billion backlog, nearly four times the size of the whole company's market capitalization.

Backlog four times market cap. That is the sentence that makes Fluor sound undervalued after a run that has already happened.

The crowd is right that the number exists. It is wrong about what the number is worth.

The Backlog Isn't Profit, and It Isn't Growing Earnings

A backlog is not money stacked in a vault. It is a queue of future revenue — work won and booked, not yet built and not yet paid. What that queue is worth depends entirely on margin, and Fluor's margin is thin. Against that $26.9 billion of booked work and a revenue run rate above $15 billion, the company guided full-year 2026 adjusted EBITDA to roughly $500–525 million. Two percent of the backlog each year. The number everyone quotes as an asset actually earns a fee.

This matters because of what happened to the stock while earnings sat still. Fluor's adjusted EBITDA for 2025 was $504 million. Its 2026 guide is $500–525 million — essentially flat, and trimmed from an earlier $525–560 million. The shares more than tripled across that same stretch. Earnings power did not move; the multiple did.

Strip out the backlog-to-market-cap slogan and Fluor no longer looks like a cheap engineer at all: roughly 25 times trailing adjusted earnings, and about 10 times enterprise value to EBITDA, in line with peers like KBR and AECOM that never needed a rescue. The discount the word "undervalued" implies was closed by the run itself.

The Safety Everyone Cheers Is What Caps the Profit

The market's favorite number inside the backlog is that 85% of it is now reimbursable, or cost-plus. Investors read this as "the legacy risk is gone," and it is. But reimbursable carries an exact translation: the client owns the cost, and Fluor collects a fee on top. Safe work, and structurally thin-margin work. The celebrated de-risking is the same decision as accepting you will never earn much on that 85%.

The remaining 15% fixed-price slice is where Fluor's real catastrophes have historically lived — the 2019 quarter that produced a $555 million loss, the restatement of its 2020 results, and the 2023 SEC penalty of $14.5 million for what the agency called "overly optimistic" cost estimates on legacy fixed-price bids. The company that is "cheap" today is the company that lost money the last time big, lumpy, fixed-price jobs ran over.

The Buyback Was Sold to You, Not Earned

There is one more reason the earnings picture looks better than the operations justify, and it is the least discussed. Fluor spent $754 million buying back shares in 2025 — a year in which it reported a GAAP net loss of $51 million, and in which buybacks exceeded even its full adjusted EBITDA of $504 million. It plans $1.4 billion more in 2026.

The cash did not come from the operation. It came from selling assets: $605 million of NuScale shares in 2025, another $1.35 billion in the first quarter of 2026, plus $175 million from exiting a Mexico joint venture. The arithmetic of the turnaround is revealing. Adjusted net earnings actually fell in 2025, to $361 million from $405 million the year before, yet adjusted earnings per share rose — because the share count was shrinking. The numerator went down, the denominator went down, and the per-share number went up.

That is not a business compounding. It is a balance sheet being liquidated and reported in per-share form.

Selling the Option Everyone Is Paying For

The premium Fluor now carries rests on a bull story of nuclear and data-center buildout — a "pick-and-shovel" ride on the power boom. Yet the purest exposure to that exact theme has already been cashed out. Fluor did not keep its stake; it sold every remaining NuScale share across 2025 and the first half of 2026. The most direct torque to small modular reactors no longer belongs to Fluor's shareholders. Investors are paying a premium for optionality management has already monetized.

Add the detail buried inside the celebrating Q2: revenue of $4.33 billion and adjusted EPS of $0.91 beat expectations and the shares jumped, but the beat carried a guide-down — full-year EBITDA reduced as the Mexico joint venture left the forecasts. Good news delivered while the number the company actually controls got smaller.

What Would Make the Crowd Wrong

Every contrarian argument should be able to lose, and this one has a clean failure condition. The bear case is dead if Fluor converts its reimbursable queue into genuine recurring cash flow and grows adjusted EBITDA through and beyond the mid-$500 millions without selling assets to do it. Then the multiple is earned, the margins are real, and the premium is justified.

What sinks the "undervalued after a 249% run" crowd instead is a different, shorter list: guidance drifting down again, buybacks draining the net-cash cushion that props up the per-share numbers, or a single large fixed-price job on Fluor's new nuclear ambitions repricing costs the way the old ones did. The narrative wants Fluor to build big, lumpy, fixed-price energy facilities again — precisely the work that broke it in 2019.

The poll that mattered here was never whether the consensus sounded reasonable. It was whether anyone still had to buy after the run already happened. Calling a stock cheap because its backlog is four times its market cap protected careers all the way up. It protects a story, not a portfolio.